Cue Biopharma (CUE) Current Leases (2019 - 2025)

Cue Biopharma has disclosed Current Leases across 7 years of filings, most recently posting $1.9 million for Q4 2025.

• Current Leases for Q4 2025 came in at $1.9 million, down 46.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 million (down 46.02% YoY), and the FY2025 annual result was $1.9 million, down 46.02% from the prior year.
• Current Leases came in at $1.9 million for Q4 2025 at Cue Biopharma, down from $2.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $5.4 million in Q1 2022 to a low of $700000.0 in Q4 2022.
• The 5-year median for Current Leases is $3.4 million (2023), against an average of $3.3 million.
• Across the five-year window, Current Leases slumped 85.81% in 2022 and jumped 381.14% in 2023, its largest moves.
• Cue Biopharma's Current Leases stood at $4.9 million in 2021, then plunged by 85.81% to $700000.0 in 2022, then surged by 381.14% to $3.4 million in 2023, then climbed by 5.11% to $3.5 million in 2024, then sank by 46.02% to $1.9 million in 2025.
• The last three Current Leases figures came in at $1.9 million (Q4 2025), $2.0 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.